LLY

998.88

-0.19%↓

JNJ

243.11

-0.23%↓

ABBV

227.62

+0.42%↑

NVS

155.44

-3.77%↓

AZN

192.99

-1.1%↓

LLY

998.88

-0.19%↓

JNJ

243.11

-0.23%↓

ABBV

227.62

+0.42%↑

NVS

155.44

-3.77%↓

AZN

192.99

-1.1%↓

LLY

998.88

-0.19%↓

JNJ

243.11

-0.23%↓

ABBV

227.62

+0.42%↑

NVS

155.44

-3.77%↓

AZN

192.99

-1.1%↓

LLY

998.88

-0.19%↓

JNJ

243.11

-0.23%↓

ABBV

227.62

+0.42%↑

NVS

155.44

-3.77%↓

AZN

192.99

-1.1%↓

LLY

998.88

-0.19%↓

JNJ

243.11

-0.23%↓

ABBV

227.62

+0.42%↑

NVS

155.44

-3.77%↓

AZN

192.99

-1.1%↓

Home・Akciju saraksts・CytomX Therapeutics Inc

CytomX Therapeutics Inc

Slēgts

SektorsVeselības aprūpe

4.87 0.41

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

4.76

Max

4.99

Galvenie mērījumi
By Trading Economics
Ienākumi	-14M -14M
Pārdošana	-13M 6M
P/E Sektora vidējais	16.767 61.417
Peļņas marža	-238.621
Darbinieki	119
EBITDA	-13M -14M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+96.11% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 16. marts

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	204M 852M
Iepriekšējā atvēršanas cena	4.46
Iepriekšējā slēgšanas cena	4.87

Ziņu noskaņojums

By Acuity

89%

11%

328 / 351 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bullish Evidence

0.7658 / N/A Atbalsts un pretestība

CytomX Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 11. marts 19:18 UTC

Galvenie tirgus virzītāji

Stryker Shares Down After Cyberattack Tied to Iran-Linked Group

2026. g. 11. marts 23:54 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 11. marts 23:54 UTC

Tirgus saruna

Nikkei May Decline on Energy Costs Concerns -- Market Talk

2026. g. 11. marts 23:51 UTC

Tirgus saruna

Gold Falls as Rising Oil Prices Spur Inflation Worries -- Market Talk

2026. g. 11. marts 23:41 UTC

Tirgus saruna

REA Bull Sees Potential Upside to Yield Guidance -- Market Talk

2026. g. 11. marts 23:37 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Futures Rise Amid Ongoing Middle East Conflict -- Market Talk

2026. g. 11. marts 23:17 UTC

Galvenie ziņu notikumi

Front-Month WTI Crude Oil Futures Rise 5.5% to $92.05/bbl

2026. g. 11. marts 23:17 UTC

Galvenie ziņu notikumi

Front-Month Crude Oil Futures Rise Amid Ongoing Middle East Conflict

2026. g. 11. marts 22:29 UTC

Tirgus saruna

Australia Shares Set to Fall in Early Trade -- Market Talk

2026. g. 11. marts 21:47 UTC

Peļņas

Liontown Resources: Market Tailwinds Strengthening Outlook

2026. g. 11. marts 21:46 UTC

Peļņas

Liontown Resources: 4 Mln Ton Per Annum Expansion Study Underway

2026. g. 11. marts 21:45 UTC

Peļņas

Liontown Resources Says FY26 Guidance Unchanged

2026. g. 11. marts 21:45 UTC

Peļņas

Liontown Resources 1H Unit Operating Costs A$985/Ton

2026. g. 11. marts 21:44 UTC

Peļņas

Liontown Resources 1H Underlying Ebitda Loss A$7.7 Million

2026. g. 11. marts 21:43 UTC

Peļņas

Liontown Resources 1H Revenue A$207.5 Million

2026. g. 11. marts 21:43 UTC

Peļņas

Liontown Resources 1H Net Loss A$184 Million

2026. g. 11. marts 21:12 UTC

Iegādes, apvienošanās, pārņemšana

Netflix Rival Strikes Deal With Google in Battle for AI Content -- Barrons.com

2026. g. 11. marts 21:10 UTC

Peļņas

Vista Gold FY25 Loss $7.5M >VGZ

2026. g. 11. marts 21:10 UTC

Peļņas

Vista Gold FY25 Loss/Shr 6c >VGZ

2026. g. 11. marts 20:50 UTC

Tirgus saruna

Galvenie ziņu notikumi

Basic Materials Roundup: Market Talk

2026. g. 11. marts 20:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 11. marts 20:27 UTC

Iegādes, apvienošanās, pārņemšana

Papa John's Draws Fresh Takeover Interest -- 2nd Update

2026. g. 11. marts 20:26 UTC

Peļņas

These Stocks Are Today's Movers: Oracle, UniFirst, Fair Isaac, Nebius, AeroVironment, Campbell's, and More -- Barrons.com

2026. g. 11. marts 20:19 UTC

Galvenie ziņu notikumi

The Strait of Hormuz Could Take Weeks -- Even Months -- to Reopen, Military Experts Say -- Barrons.com

2026. g. 11. marts 20:15 UTC

Peļņas

This Physical AI Stock Jumped on Earnings. The Robots Are Coming. -- Barrons.com

2026. g. 11. marts 20:12 UTC

Galvenie ziņu notikumi

Stock Market Today: Oil Prices Push Higher Despite IEA Oil Release Headline -- WSJ

2026. g. 11. marts 19:31 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Futures Gain Despite IEA's Planned Release of Reserves -- Market Talk

2026. g. 11. marts 19:01 UTC

Tirgus saruna

Galvenie ziņu notikumi

U.S. Natural Gas Gains With Middle East Conflict in View -- Market Talk

2026. g. 11. marts 18:59 UTC

Iegādes, apvienošanās, pārņemšana

Berkshire's Deal for Occidental Chemicals Unit Is a Winner as Chemical Stocks Surge -- Barrons.com

2026. g. 11. marts 18:43 UTC

Galvenie ziņu notikumi

Chubb Named Lead Insurer for U.S. Plan to Protect Oil Tankers in Strait of Hormuz -- Barrons.com

Salīdzinājums

Cenas izmaiņa

CytomX Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

96.11% augšup

Prognoze 12 mēnešiem

Vidējais 9.57 USD 96.11%

Augstākais 10 USD

Zemākais 7 USD

Pamatojoties uz 7 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi CytomX Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

7 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 7 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam CytomX Therapeutics Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

0.7658 / N/AAtbalsts un pretestība

Bullish events outweigh bearish events.

All events are bullish.

Recent bullish events outweigh bearish events.

Noskaņojums

By Acuity

328 / 351 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par CytomX Therapeutics Inc

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.